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Background: Noncompetitive N-methyl-D-aspartate (NMDA) receptor antagonists evoke a behavioral and
neurobiological syndrome in experimental animals. We previously reported that phencyclidine (PCP), an NMDA
receptor antagonist, increased locomotor activity in wildtype (WT) mice but not GluN2D subunit knockout mice.
Thus, the aim of the present study was to determine whether the GluN2D subunit is involved in PCP-induced
motor impairment.
Results: PCP or UBP141 (a GluN2D antagonist) induced potent motor impairment in WT mice but not GluN2D
KO mice. By contrast, CIQ, a GluN2C/2D potentiator, induced severe motor impairment in GluN2D KO mice but
not WT mice, suggesting that the GluN2D subunit plays an essential role in the effects of PCP and UBP141,
and an appropriate balance between GluN2C and GluN2D subunits might be needed for appropriate motor
performance. The level of the GluN2D subunit in the mature mouse brain is very low and restricted. GluN2D
subunits exist in brainstem structures, the globus pallidus, thalamus, and subthalamic nucleus. We found that
the expression of the c-fos gene increased the most among PCP-dependent differentially expressed genes
between WT and GluN2D KO mice, and the number of Fos-positive cells increased after PCP administration
in the basal ganglia motor circuit in WT mice but not GluN2D KO mice.
Conclusion: These results suggest that the GluN2D subunit within the motor circuitry is a key subunit for PCP-induced
motor impairment, which requires an intricate balance between GluN2C- and GluN2D-mediated excitatory outputs.
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The N-methyl-D-aspartate (NMDA) receptor channel is
involved in various physiological functions, including lear-
ning and memory. NMDA receptors are primarily com-
posed of GluN1, GluN2 (A-D), and GluN3 subunits. The
GluN1 subunit is expressed ubiquitously, whereas GluN2
subunit expression is region- and cell-specific. Additionally,
the temporal expression of each subunit varies [1]. Among
the GluN2 (A-D) subunits, the physiological role of the* Correspondence: yamamoto-hd@igakuken.or.jp
1Addictive Substance Project, Tokyo Metropolitan Institute of Medical
Science, 2-1-6 Kamikitazawa, Setagaya-ku, Tokyo 156-8506, Japan
Full list of author information is available at the end of the article
© 2013 Yamamoto et al.; licensee BioMed Cen
Creative Commons Attribution License (http:/
distribution, and reproduction in any mediumGluN2D subunit is not fully understood because of its
unique properties. In the rodent brain, the GluN2D sub-
unit is expressed during postnatal periods. However, as the
animal ages, the levels of GluN2D mRNA and protein de-
crease. In mature brains, significant levels of GluN2D sub-
units are mainly restricted to diencephalic, mesencephalic,
and brainstem structures, particularly the globus pallidus,
thalamus, subthalamic nucleus, and superior colliculus [1].
GluN2D knockout (KO) mice are viable and exhibit no ob-
vious histological abnormalities [2]. However, these KO
mice exhibit a reduction of spontaneous locomotor activity
in a novel environment and less sensitivity to stress intral Ltd. This is an open access article distributed under the terms of the
/creativecommons.org/licenses/by/2.0), which permits unrestricted use,
, provided the original work is properly cited.
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swim test [2,3].
Phencyclidine (PCP) has been extensively used as a
pharmacological model of schizophrenia because of its
ability to evoke the positive and negative symptoms of
schizophrenia and characteristic cognitive deficits of this
illness observed in humans [4,5]. However, NMDA re-
ceptor antagonists evoke a behavioral syndrome in ex-
perimental animals characterized by hyperlocomotion
and the disruption of prepulse inhibition of the startle
response [6,7]. Chronic exposure to PCP intensely af-
fects the relative immunoreactivity of the GluN2 subunit
in the frontal cortex. Following PCP treatment, GluN2D
immunoreactivity and protein expression increase sig-
nificantly and induce a shift to a predominance of the
GluN2D subunit in the frontal cortex [8]. However, the
possible role of the GluN2D subunit in PCP-induced
changes in gene expression and the brain networks in-
volved in these changes remain unexplored.
We previously reported that the NMDA receptor an-
tagonist PCP significantly increased extracellular levels
of dopamine in the striatum and prefrontal cortex in
wildtype (WT) mice but not GluN2D KO mice. Further-
more, acute and repeated administration of PCP did not
increase locomotor activity in GluN2D KO mice [9].
In the present study, we performed the rotarod test,
gene expression analyses, and Fos immunohistochemis-
try in WT and GluN2D KO mice to elucidate the role of
the GluN2D subunit in PCP-induced behavioral and
neurobiological effects. The results indicated that the
GluN2D subunit of the NMDA receptor plays an impor-
tant role in PCP-induced motor impairment and PCP-
induced abnormal gene expression. PCP-induced motor
impairment was attenuated in GluN2D KO mice by pre-
venting PCP-induced excitation via the GluN2D subunit
in the neural circuit that includes the motor loop.
Results
Pharmacological modulation of motor performance using
PCP and UBP141
Motor impairment was measured by placing WT and
GluN2D KO mice on a fixed-speed rotarod (12 rpm)
and monitoring their performance for 300 s, 30 min
after saline or PCP administration. Saline injections did
not affect motor performances. At a dose of 3 or 5 mg/kg,
PCP led to motor impairment in the rotarod test (Figure 1B).
PCP-injected GluN2D KO mice performed better than
PCP-injected WT mice. Significant differences in motor im-
pairment were observed between WT and GluN2D KO
mice, based on Fisher’s exact test (p < 0.05 at both doses;
dependence on genotype).
The UBP141 solution (3 mM) was freshly prepared
and injected intracisternally under ether anesthesia.
Motor impairment was measured by placing WT andGluN2D KO mice on a fixed-speed rotarod (0 rpm and
6 rpm) and monitoring their performance for 300 s,
30 min after UBP141 administration. Motor performance
was maintained after vehicle injections. An intracisternal
injection of 3 mM UBP141 solution (20 μl) resulted in
motor impairment in seven of 10 WT mice at 0 rpm and
eight of 9 WT mice at 6 rpm (Figure 1C). In contrast,
UBP141 did not cause motor impairment in GluN2D KO
mice at 0 rpm (n = 9) and five of eight KO mice at 6 rpm
(Figure 1C). The differences in UBP141-induced motor
impairment between WT and GluN2D KO mice were sig-
nificant at 0 rpm and 6 rpm (Fisher’s exact test, p = 0.0031
and 0.049, respectively; dependence on genotype).
The CIQ solution and its vehicle were freshly prepared
and administered in WT and GluN2D KO mice. CIQ did
not cause hyperlocomotion, but it markedly reduced motor
performance in 13 of 15 GluN2D KO mice (Figure 1D). In
contrast, CIQ did not cause motor impairment in five of
eight WT mice. The difference in CIQ-induced motor
impairment between WT and GluN2D KO mice was
significant (Fisher’s exact test, p = 0.0026; dependence
on genotype).
Altered gene expression in GluN2D KO mice in response
to PCP
We explored the alterations in gene expression in
GluN2D KO mice that could be responsible for the
differential behavioral responses to PCP. We first per-
formed a preliminary cDNA array experiment using
mRNA derived from the striata in WT and GluN2D
KO mice with or without PCP treatment. Compared
with saline-injected WT mice, saline-injected GluN2D
KO mice showed increased expression of 247 tran-
scripts (Figure 2A; KOS/WS). An injection of PCP
(10 mg/kg, s.c.) in WT mice and KO mice increased
the expression of 193 and 46 transcripts, respectively
(Figure 2A; WPCP/WS or KOPCP/KOS). The expres-
sion of a large number of genes was increased in the
saline-injected GluN2D KO and PCP-injected WT mice.
Both groups shared 36% and 46% of the increased tran-
scripts, respectively. However, the increased gene expres-
sion pattern in PCP-injected GluN2D KO mice (KOPCP/
KOS) differed from PCP-injected WT mice (WPCP/WS).
Interestingly, 47 and 24 of the transcripts that showed in-
creased expression in PCP-injected WT mice (WPCP/
WS) and saline-injected GluN2D KO mice (KOS/WS), re-
spectively, showed an opposite trend in PCP-injected
GluN2D KO mice (Figure 2A). Figure 2B illustrates the re-
lationship between the effect of PCP in WT and KO mice.
Each control consisted of a WT or KO mouse. Linear
regression analysis showed that the data fit a straight
line (r = −0.564). The expression ratios of all of the tran-
scripts demonstrated a weak inverse relationship in re-
sponse to PCP between WT and KO mice. The probes in
Figure 1 The effects of PCP, UBP, and CIQ on motor performance. (A) Wildtype mice and KO mice did not display significant differences in
motor learning. WT, wildtype mice (n = 60); KO, GluN2D knockout mice (n = 55). (B) Ataxic effects of phencyclidine (PCP) at 3.0 mg/kg (n = 15 WT,
n = 17 KO) and 5.0 mg/kg (n = 16 WT, n = 15 KO) in the rotarod test at 12 rpm. A significant effect of genotype was observed in the PCP-induced
decrease in time at the two doses tested (p < 0.05 at both doses, dependence on genotype; Fisher’s exact test). Twenty-four to 72 h after PCP
injection, the WT and KO mice were injected with saline. Motor performance was not affected by saline injection. Almost all of the mice
showed maximal performance at 12 rpm (> 300 s), and the remaining mice showed normal performance (> 200 s). (C) Effect of UBP in the
rotarod test at 0 rpm (n = 10 WT, n = 9 KO) and 6 rpm (n = 9 WT, n = 8 KO). The differences between WT and GluN2D KO mice in UBP141-induced
motor impairment were significant at 0 and 6 rpm (p < 0.05 at both speeds, dependence on genotype; Fisher’s exact test). The vehicle injection did not
affect motor performances in WT and KO mice (both genotypes: > 300 s at 12 rpm, n= 5; > 200 s at 12 rpm, n= 2; < 200 s at 12 rpm, n= 1). (D) Effect of
CIQ in the rotarod test at 12 rpm (n= 8 WT, n= 15 KO). The difference between WT and GluN2D KO mice in CIQ-induced motor impairment was
significant (p < 0.05, dependence on genotype; Fisher’s exact test). The vehicle injection did not affect motor performances in WT and KO
mice (WT: > 300 s at 12 rpm, n = 5; > 200 s at 12 rpm, n = 2; KO: > 300 s at 12 rpm, n = 11; > 200 s at 12 rpm, n = 2).
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Figure 2 The preliminary cDNA array experiment. (A) Venn
diagrams that illustrate the distribution of altered transcripts in the
striatum. The diagrams are derived from the gene expression data of
the cDNA array data (preliminary experiment). The red circle or blue
circle contains the genes that exhibited increased or decreased
expressions more than 1.3-fold or less than 0.7-fold compared with
saline-injected control mice, respectively. The numbers in parentheses
show the number of changed transcripts in each group. WPCP,
PCP-injected WT mice; WS, saline-injected WT mice; KOS, saline-injected
GluN2D KO mice; KOPCP, PCP-injected GluN2D KO mice. (B) Scatter plot
of the effect of PCP on gene expression in WT mice (X-axis) and GluN2D
KO mice (Y-axis). The scatter plot of all of the transcripts shows the ratios
between the expression of each gene in WPCP and the expression of
each gene in WS and the ratios between the expression of each gene
in KOPCP and the expression of each gene in KOS. Each point shows
the fold-change (%) using the cDNA array data (preliminary experiment),
which included globally normalized data. The associations between the
parameters were analyzed using Karl Pearson’s correlation or Spearman’s
rank correlation. Gene expression in WPCP was negatively correlated
with gene expression in KOPCP (r = −0.564, p < 0.01).
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not fully cover genes. Therefore, we next used a commer-
cial array (MouseRef-8 BeadChip with greater than 24,000
probes) provided by Illumina.We utilized WTand GluN2D KO mouse striata to profile
the DEGs following PCP administration in WT and
GluN2D KO mice. Total RNAs from the striata of WT and
GluN2D KO mice obtained 2 h after an injection of saline
or PCP (10 mg/kg, s.c.) were analyzed using a microarray-
based screen with Illumina MouseRef-8. An Additional file
1: Table S1 shows this in more detail [see Additional file 1:
Table S1]. This comparative analysis revealed the differen-
tial expression profiles of 51 genes following PCP adminis-
tration, with 40 genes upregulated more than 1.3-fold and
11 genes downregulated less than 0.7-fold in WT and
GluN2D KO mice. The two genotypes were found to share
only 18% of the genes in the PCP-induced increase in the
expression profile. Correlation analysis revealed that the
PCP-induced increase in gene expression in WT and
GluN2D KO mice was inversely associated (r= −0.46).
Real-time qRT-PCR analyses
To validate the microarray data, the RNA levels of some of
the candidate DEGs were analyzed by qRT-PCR. From the
DNA array results using the striata, 23 genes that were up-
regulated more than 1.3-fold or downregulated less than
0.7-fold in WT and GluN2D KO mice were chosen. The
qRT-PCR results (Table 1) confirmed the microarray data
for both the upregulation and downregulation of the se-
lected genes. The expression of Hace1, Osbpl8, Smpd4, and
Slc17 in the striatum in GluN2D KO mice was significantly
increased. Among the 23 genes, 17 were upregulated, and
one was downregulated with PCP treatment. Several of
these 17 genes in GluN2D KO mice showed significantly
altered expression in response to PCP compared with
their expression profiles in WT mice.
Similarly, we evaluated total RNA derived from pooled
frontal cortices in the qRT-PCR analyses (Table 2). Using
the same primer sets that we used for the striatum, 13 genes
were found to be upregulated by PCP treatment. As a re-
sult, we found four candidate genes from the cDNA array
and confirmed their expression using real-time RT-PCR.
These four genes are not involved in the MouseRef-8 Bead-
Chip. Furthermore, we found 23 candidate genes from the
MouseRef-8 BeadChip with greater than 24,000 probes.
Bioinformatics analyses
The gene expression data shown in Tables 1 and 2 were
uploaded into MetaCore 5.0 software (GeneGo pathway
analysis). Graphical representations of the molecular rela-
tionships between genes were generated in a network built
by the auto expand path algorithm, allowing 50 nodes
(Figure 3). The network analysis of the 16 genes in Figure 3
showed that eight genes were directly linked to nuclear
factor-κB (NF-κB; Figure 3A). Downstream of NF-κB was
indirectly linked to 14-3-3 as one node and then from 14-
3-3 spread to EGR4 or DSIPI and Sestrin 1. However, sig-
nificantly altered processes for KOPCP/KOS were not
Table 1 qRT-PCR validation of genes selected from fold change analysis of microarray data in the striatum
Symbol Definition n KOS/WS(vs. WS) %
WPCP/WS
(vs. WS) %
KOPCP/KOS % (vs. WPCP/WS)
Significantly changed gene expressions of NR2D KO mice
Slc17 vesicular glutamate transporter 2 4 210 ± 39 * 117 ± 14 49 ± 12 c
Hace1 HECT domain and ankyrin repeat containing, E3 ubiquitin protein ligase 1 7 157 ± 12 ** 101 ± 9 84 ± 5 a
Smpd4 sphingomyelin phosphodiesterase 4 (FLJ20297) 6 147 ± 4 ** 105 ± 7 86 ± 5 b
Osbpl8 oxysterol binding protein-like 8 (ORP8), transcript variant 1 4 136 ± 8 ** 112 ± 10 68 ± 7 c
Significantly changed gene expressions induced by PCP of wild-type mice
Fos FBJ osteosarcoma oncogene 4 110 ± 8 283 ± 40 * 109 ± 12 c
Txnip thioredoxin interacting protein (Txnip), transcript variant 1 4 137 ± 5 * 211 ± 29 ** 122 ± 11 b
Pglyrp1 peptidoglycan recognition protein 1 (PGRP-S) 4 120 ± 5 176 ± 7 ** 126 ± 6 c
Fosb FBJ osteosarcoma oncogene B 3 122 ± 3 162 ± 29 ** 74 ± 9 b
Sesn1 sestrin 1 4 116 ± 6 155 ± 11 ** 120 ± 7 b
Arrdc arrestin domain containing 3 (mKIAA1376) 4 133 ± 8 ** 149 ± 10 ** 95 ± 9 c
Zbtb4 zinc finger and BTB domain containing 4 4 115 ± 5 141 ± 3 * 109 ± 6 c
Bag-3 Bcl2-associated athanogene 3 4 107 ± 3 132 ± 5 ** 108 ± 7 b
Ddit4 DNA-damage-inducible transcript 4 (REDD1) 4 124 ± 10 184 ± 27 ** 142 ± 19 a
Gadd45g growth arrest and DNA-damage-inducible 45 γ 4 119 ± 5 170 ± 15 * 126 ± 26 a
Tsc22d3 TSC22 domain family, member 3, transcript variant 1 (DSIPI) 4 100 ± 4 154 ± 18 * 148 ± 17 a
Cbr3 carbonyl reductase 3 4 102 ± 5 152 ± 6 ** 149 ± 17 a
Cfp complement factor properdin (Properdine) 4 133 ± 34 142 ± 14 * 126 ± 34 a
Sbf1 SET binding factor 1 6 91 ± 10 141 ± 14 * 217 ± 65 a
Slc2a1 solute carrier family 2 (GLUT1) 4 103 ± 8 140 ± 10 ** 136 ± 14 a
Sgk1 serum/glucocorticoid regulated kinase 1 4 120 ± 11 138 ± 9 ** 114 ± 16 a
Rgc32 RIKEN cDNA 1190002H23 gene 4 104 ± 4 133 ± 7 * 125 ± 12 a
Egr1 early growth response 1(zif-268) 4 114 ± 11 60 ± 5 * 57 ± 10 a
Significantly changed gene expressions induced by PCP of GluN2D KO mice
Egr4 early growth response 4 4 121 ± 9 82 ± 10 48 ± 4 b
Data are expressed as the mean percentage ± SEM relative to the saline treated controls.
Compared to WS controls; *, p <0.05. **, p <0.01.
WPCP/WS vs. KOPCP/KOS; a, not significant. b, p <0.05. c, p <0.01.
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generated a network (Figure 3B). This network included
TXNIP (an oxidative stress mediator), REDD1 (which pro-
motes neuronal cell death), and GADD45γ (which is in-
volved in the regulation of growth and apoptosis). These
analyses indicated that PCP is a stress factor that induces
stress responses and is involved in apoptosis in WT mice.
Among the PCP-induced changes in gene expressions,
Fos was most distinguishable between WT and GluN2D
KO mice. Therefore, we chose Fos for the immunohisto-
chemical analysis.
Induction of Fos by PCP administration
Photomicrographs and semiquantitative analyses of
Fos expression are shown in Figures 4 and 5. PCP
(10 mg/kg, s.c.) markedly increased the density of Fos-
positive cells in the motor cortex and cingulate cortex andmoderately increased the density of Fos-positive cells in
the subthalamic nucleus, and thalamus in WT mice
(Figures 4EG and 5EF). However, the Fos ratio was
scarcely increased in the striatum (Figure 5). Two-way
ANOVA of the Fos data in the motor cortex indicated
a significant effect of PCP treatment (effect of PCP, F1,15 =
10.59, p = 0.0053; PCP-genotype interaction, F1,15 = 7.18,
p = 0.017). Further, post hoc testing by Scheffe’s test re-
vealed that PCP significantly increased Fos density in the
motor cortex of WT mice (p = 0.0006). In the cingulate
cortex and subthalamic nucleus, two-way ANOVA indi-
cated a significant effect of PCP treatment (cingulate cor-
tex, F1,16 = 29.17, p = 0.0001; subthalamic nucleus, F1,16 =
11.44, p = 0.0038, respectively. no PCP-genotype inter-
action). Due to unequal variance, we used Kruskal-Wallis
nonparametric test. It indicated that PCP significantly in-
creased Fos density in the cingulate cortex (p = 0.024) and
Table 2 qRT-PCR analysis of genes using the frontal cortex (the same genes in Table 1)
Symbol Definition n KOS/WS(vs. WS) %
WPCP/WS
(vs. WS) %
KOPCP/KOS % (vs. WPCP/WS)
Significantly changed gene expressions induced by PCP of wild-type mice
Fos FBJ osteosarcoma oncogene 4 89 ± 7 271 ± 16 ** 179 ± 5 c
Fosb FBJ osteosarcoma oncogene B (Fosb) 3 98 ± 7 246 ± 69 ** 134 ± 19 a
Ddit4 DNA-damage-inducible transcript 4 (REDD1) 3 112 ± 5 200 ± 8 ** 164 ± 4 b
Egr4 early growth response 4 4 107 ± 19 164 ± 56 ** 86 ± 3 b
Tsc22d3 TSC22 domain family, member 3, transcript variant 1 (DSIPI) 4 100 ± 7 209 ± 24 * 190 ± 15 a
Gadd45g growth arrest and DNA-damage-inducible 45 γ 4 103 ± 2 189 ± 25 * 146 ± 7 a
Cfp complement factor properdin (Properdine) 4 105 ± 19 151 ± 9 ** 126 ± 20 a
Slc2a1 solute carrier family 2 (GLUT1) 4 93 ± 5 149 ± 8 ** 150 ± 5 a
Txnip thioredoxin interacting protein, transcript variant 1 4 106 ± 8 143 ± 16 ** 126 ± 10 a
Bag-3 Bcl2-associated athanogene 3 4 91 ± 6 142 ± 6 ** 128 ± 6 a
Pglyrp1 peptidoglycan recognition protein 1 (PGRP-S) 3 93 ± 5 139 ± 12 ** 128 ± 12 a
Arrdc arrestin domain containing 3 (mKIAA1376) 3 110 ± 1 136 ± 14 * 115 ± 14 a
Rgc32 RIKEN cDNA 1190002H23 gene 4 97 ± 6 131 ± 7 * 123 ± 6 a
Significantly changed gene expressions induced by PCP of NR2D KO mice
Egr1 early growth response 1(zif-268) 4 94 ± 8 87 ± 8 67 ± 3 a
Data are expressed as the mean percentage ± SEM relative to the saline treated controls.
Compared to WS controls; *, p <0.05. **, p <0.01.
Compared to WS controls; *, p <0.05. **, p <0.01. WPCP vs. KOPCP; a, not significant. b, p <0.05. c, p <0.01.
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nally, two-way ANOVA of Fos-data in the thalamus indi-
cated a significant PCP-genotype interaction (F1,12 = 10.74,
p = 0.0066) and followed by Scheffe’s test, a significant in-
crease in GluN2D KO mice treated with saline compared
to WT mice (p = 0.0255) (Figure 4G). Two-way ANOVA of
Fos-data in the striatum indicated no main effect and no
PCP-genotype interaction and followed by Scheffe’s test, a
significant increase in GluN2D KO mice treated with saline
compared to WT mice (p = 0.0240) (Figure 5G). In the
present study, the PCP-induced increase in the number of
Fos-positive cells was suppressed to varying degrees in the
observed brain areas in GluN2D KO mice.Induction of c-fos mRNA by UBP141, CIQ, and PCP with
dantrolene administration determined by qRT-PCR
The levels of c-fos mRNA were examined by qRT-PCR
in the striatum and thalamus in WT and GluN2D KO
mice. Intracisternal injection of UBP141 enhanced c-fos
expression in the thalamus and striatum in WT mice
(F1,11 = 7.102, p = 0.016, and F1,11 = 4.585, p = 0.048, re-
spectively) but not in GluN2D KO mice (Figure 6A). We
then used CIQ, a potentiator of NR2C/2D subunits. CIQ
markedly enhanced c-fos expression in the thalamus and
striatum in both WT and GluN2D KO mice (Figure 6B).
In the thalamus and striatum, two-way ANOVA indi-
cated a significant effect of CIQ treatment (F1,19 = 112.59,
p < 0.0001, and F1,19 = 197.01, p < 0.0001, respectively).In the present study, we found substantial genotype-
dependent differences in PCP-induced c-fos expression.
This difference might have been secondary to PCP’s dif-
ferential genotypic effects on hyperlocomotion. Therefore,
we injected mice with dantrolene before PCP administration
to investigate the effect of hyperlocomotion on c-fos expres-
sion stimulated by PCP. Dantrolene acts as muscle relaxant
and is used for malignant hyperthermia. The therapeutic ac-
tion of dantrolene appears to be attributable to its ability to
bind to an amino-terminal sequence of skeletal ryanodine
receptors [11]. Dantrolene completely blocked PCP-induced
hyperlocomotion in WT mice (n =3). Dantrolene itself did
not increase c-fos expression except in the thalamus in
GluN2D KO mice (Figure 6C). Dantrolene did not inhibit
PCP-induced c-fos expression in the thalamus or striatum in
WT mice or thalamus in GluN2D KO mice (Figure 6C, D).
Therefore, the substantial genotype differences in PCP-
induced c-fos expression were not secondary to PCP’s diffe-
rential genotypic effects on hyperlocomotion. In addition,
Numeric data of Figure 6(A-D) and these actin data are
shown in Additional file 2: Table S2.
Discussion
The pharmacological activity of acute PCP administra-
tion in mice can be broadly classified into three symp-
toms: cognitive dysfunction, hyperlocomotion, and motor
impairment. In the present study, we focused on motor
impairment caused by PCP. The main findings were that
PCP-induced motor impairment was markedly reduced in
Figure 3 (See legend on next page.)
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Figure 3 Network developed in MetaCore based on the genes listed in (A) Table 1 and (B) Table 2. Interactions between nodes are
shown by arrows, indicating activation (green), inhibition (red), and unspecified effects (gray). Detailed information on the symbols can be found
at http://pathwaymaps.com/pdf/MC_legend.pdf (accessed July 7, 2013). A gene in the networks that contain a small circle was verified by
quantitative reverse-transcription polymerase chain reaction. The small red circle indicates upregulation. The small blue circle indicates
downregulation. The small mixed-color circle indicates positively and negatively regulated expression dependent on genotype.
Figure 4 Analyses of Fos induction in various brain regions in wildtype and GluN2D knockout mice. The photomicrographs illustrate
the immunohistochemical labeling of Fos in coronal sections of the thalamus. The boxes are shown in panels a-i are at higher magnification.
A schematic representation of the paraventricular thalamic nucleus (PV), thalamus (Th), and subthalamic nucleus (Sth) is shown in panel H. The
number of Fos-positive cells per square millimeter was determined in the respective brain areas (E–G) and normalized to the number in saline-treated
mice (I). Open bars, wildtype (WT) mice; closed bars, GluN2D KO mice. The results are expressed as the mean ± SEM ratio between the density of Fos-positive
neurons in PCP-treated mice to the density of Fos-positive neurons in saline-injected mice (n = 4–6). One-way ANOVA of the PCP-induced increase in
Fos-positive cells indicated a significant effect of genotype in the thalamus (Kruskal-Wallis nonparametric ANOVA followed by Scheffe’s test,
p = 0.0209, unequal variance). *p < 0.05. Scale bars = 1 mm and 200 μm in panel D and d, respectively. The brain regions are defined as indicated by
the images in the atlas [10].
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Figure 5 Analyses of Fos induction in various brain regions in wildtype and GluN2D knockout mice. The photomicrographs illustrate the
immunohistochemical labeling of Fos in coronal sections of the forebrain. The boxes are shown in panels a-i are at higher magnification. A schematic
representation of the cingulate cortex (Cg), motor cortex (M), and striatum (Str) is shown in panel H. The number of Fos-immunoreactive cells per
square millimeter in PCP-treated mice was determined in the respective brain regions (E–G) and normalized to the number in saline-treated mice
(I). Open bars, wildtype (WT) mice; closed bars, GluN2D KO mice. The results are expressed as the mean ± SEM ratio between the density of
Fos-positive neurons in PCP-treated mice to the density of Fos-positive neurons in saline-injected mice (n = 4–6). One-way ANOVA of the
PCP-induced increase in Fos-positive cells indicated a significant effect of genotype in the striatum (F1,6 = 75.8, p = 0.0001). *p < 0.05, ***p < 0.001.
Scale bars = 1 mm and 200 μm in panel D and d, respectively. The brain regions are defined as indicated by the images in the atlas [10].
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induced enhanced expression of c-fos, one of the most po-
tent PCP-dependent DEGs between the two genotypes,
was suppressed in several areas of the motor circuit in
GluN2D KO mice. These findings indicate that ablation of
the GluN2D subunit blocks the PCP-dependent abnormal
neuronal activation in the motor circuit and prevents motor
impairment. Thus, GluN2D subunit-containing NMDAreceptors appear to play a key role in PCP-induced
motor impairment.
PCP-induced motor impairment is attributable to
blockade of the GluN2D subunit
Although PCP is a nonselective blocker of GluN2(A-D)-
containing NMDA receptors [12], PCP-induced motor
impairment was reduced in GluN2D KO mice, suggesting
Figure 6 Quantitative RT-PCR demonstrated the transcription of c-fos expression in the thalamus and striatum. The ratio of c-fos/actin
transcripts is expressed as the mean ± SEM fold change from saline controls in WT mice. (A) Two hours after the injection of UBP141 (3 mM,
20 μl, i.c.), a significant increase in c-fos mRNA was observed in the thalamus and striatum in WT but not KO mice (*p < 0.05). (B) CIQ (20 mg/kg,
i.p.) markedly increased c-fos mRNA expression in the thalamus and striatum in WT and KO mice (**p < 0.01). No genotype difference was
found between WT and KO mice. (C) PCP (10 mg/kg, s.c.) significantly increased c-fos mRNA expression in the thalamus with or without
dantrolene (**p < 0.01), which completely suppressed PCP-induced hyperlocomotion. In the thalamus, dantrolene (5 mg/kg, i.p.) itself induced the
slight activation of c-fos expression in GluN2D KO mice (*p < 0.05). (D) PCP (10 mg/kg, s.c.) significantly increased c-fos mRNA expression in the striatum
in WT mice with or without dantrolene, but PCP had no effect in the striatum in GluN2D KO mice.
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ment mainly by blocking the GluN2D subunit. Watanabe
et al. reported that the expression of GluN2D subunit
mRNA is clearly detectable in the diencephalon and brain-
stem in the embryonic brain, but GluN2D subunit expres-
sion is nearly abolished in the mature rodent brain [1]. In
the present study, the striatum had low expression levels of
the GluN2D subunit. Interestingly, rather low levels of the
GluN2D subunit play an important role in PCP-induced
abnormal behaviors.
Ablation of the GluN2D subunit did not produce motor
impairment in mature GluN2D KO mice, but change in
gene expression remained. In the striatum of GluN2D KO
mice, we found increased expression of four genes: Slc17,
Hace1, Smpd4, and Osbpl8. Among these genes, the ex-
pression of vGluT2 (Slc17), which encodes a transporterof cytosol glutamate into synaptic vesicles, was strongly
increased in the striatum but not frontal cortex in mature
GluN2D KO mice. Mice that heterozygously lack vglut2
have been reported to show an increased locomotor re-
sponse to amphetamine and increased sensitivity to the
startle-disrupting effects of MK-801 [13]. However, be-
cause acute and repeated PCP administration does not in-
crease locomotor activity in GluN2D KO mice [9], the
increased expression of vGluT2 in the striatum in GluN2D
KO mice may negatively regulate PCP-induced locomotor
activity. The other three genes, Hace1, Smpd4, and
Osbpl8, have not yet been investigated with regard to
motor impairment.
To investigate the role of the GluN2D subunit in PCP-
induced motor impairment while avoiding the effects of
GluN2D subunit ablation during development, we used
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rotarod test. UBP141 is a competitive glutamate bind-
ing site antagonist, displaying seven-fold higher select-
ivity for GluN2D-containing receptors over GluN2B- or
GluN2A-containing receptors [14]. In the present study,
UBP141 induced severe motor impairment in WT mice
but not GluN2D KO mice, suggesting that the blockade of
GluN2D-containing NMDA receptors caused motor im-
pairment without developmental adaptations. Although
the affinities of UBP141 for the GluN2C and GluN2D sub-
units are within a similar range, UBP141 likely inhibits the
GluN2C subunit as well as the GluN2D subunit. The find-
ing that UBP141 did not induce severe motor impairment
in GluN2D KO mice suggests that inhibition of GluN2C
subunit-containing NMDA receptors may not be involved
in motor impairment. If so, then the inhibition of GluN2C
subunit-containing NMDA receptors by PCP does not ap-
pear to play a significant role in PCP-induced motor
impairment. Therefore, the inhibition of the GluN2D
subunit by PCP appeared to participate in PCP-induced
motor impairment in WT mice.
CIQ selectively potentiates GluN2C and GluN2D sub-
unit. The EC50 values for the potentiation of GluN2C-
and GluN2D-containing receptors are 2.7 and 2.8 μM,
respectively [15]. CIQ induced motor impairment in
GluN2D KO mice but not WT mice, suggesting that
CIQ-induced motor impairment is not caused by simple
potentiation of the GluN2C subunit but rather by an im-
balance of potentiation of the GluN2C subunit and
GluN2D subunit. The GluN2C subunit mainly exists in the
cerebellum, and GluN2D subunit exists in the thalamus,
globus pallidus, and subthalamic nucleus. Therefore, the
potentiation of the GluN2C or GluN2D subunit may affect
different neural circuits.
Induction of c-fos by inhibition of the GluN2D subunit or
potentiation of the GluN2C subunit
UBP141 administration increased c-fos expression in the
thalamus and striatum in WT mice but not GluN2D KO
mice. Although UBP141 inhibits GluN2D and GluN2C
at similar concentrations (2.2-fold selectivity) in vitro,
UBP141 is able to inhibit GluN2C subunit-containing
NMDA receptors in GluN2D KO mice. However, UBP141
did not increase c-fos mRNA in GluN2D KO mice
(Figure 6A). In contrast, CIQ, a potentiator of GluN2C/
2D subunits, induced c-fos expression to a similar extent
in WT and KO mice (Figure 6B). Therefore, CIQ likely po-
tentiated GluN2C subunit-containing NMDA receptors in
GluN2D KO mice. These results suggest that potentiation
of the GluN2C subunit and inhibition of the GluN2D sub-
unit induce neural excitation. However, the mechanisms of
c-fos induction by these compounds can be different. UBP-
141 has a similar mechanism of action as PCP. That is,
UBP-141 blocks the GluN2D subunit-containing NMDAreceptor complex in the GABA neurons. The suppression
of GABA neurons then disinhibits glutamatergic neurons,
and activated glutamatergic neurons induce neural excita-
tion. CIQ enhanced the function of the NMDA receptor
complex by acting on GluN2C/2D subunits. In the basal
ganglia and cerebellum, direct potentiation of the GluN2C/
2D subunit-containing NMDA receptor complex in gluta-
matergic neurons may induce c-fos expression in the
thalamus and subsequently in the striatum. Thus, these
increases in c-fos induction by UBP141 or CIQ are
likely attributable to the activation of different neural
circuits.
CIQ potentiated the function of GluN2C/2D subunit-
containing NMDA receptors in WT mice but potenti-
ated only the GluN2C subunit in GluN2D KO mice. In
the present study, we found that the inhibition of GluN2D
subunit-containing NMDA receptors in the motor loop or
potentiation of GluN2C subunit-containing NMDA recep-
tors likely in the cerebellum loop induced motor impair-
ment. These two neural circuits (i.e., the basal ganglia and
cerebellum) are well known to be important for coopera-
tive movements (Figure 7). The balance between the
GluN2C subunit-rich cerebellum loop and GluN2D
subunit-containing basal ganglia circuit would be needed
for appropriate motor performance.
PCP-induced c-fos expression and basal ganglia circuitry
The immunohistochemical analysis of Fos revealed that
the PCP-induced increase in the number of Fos-positive
cells was suppressed in the observed brain areas in
GluN2D KO mice, including the striatum, thalamus,
motor cortex, and subthalamic nucleus (Figures 4 and 5).
However, the numbers of Fos-positive cells in the striatum
and thalamus of saline-treated GluN2D KO mice were sig-
nificantly increased compared with WT mice (Figure 4(G)
and Figure 5(G), respectively). There is a possibility that
the existence of a ceiling effect in GluN2D KO mice might
mask the PCP-induced increases in GluN2D KO mice.
Nevertheless, the measurements of c-fos mRNA by
qRT-PCR indicated no significant increase in the thal-
amus or striatum in GluN2D KO mice (Figure 6). There-
fore, the suppression of PCP-induced c-fos expression in
KO mice was unlikely attributable to the ceiling effect.
Changes in c-fos mRNA are more quickly linked to neural
excitation than Fos protein expression. These c-fos mRNA
results suggested that PCP-induced excitation in the thal-
amus and striatum in GluN2D KO mice was suppressed
as well as in other areas of the motor loop (i.e., subtha-
lamic nucleus and motor cortex) in GluN2D KO mice.
On the other hand, the observed genotypic differences
in the expression of c-fos and activation of Fos might
be secondary to PCP’s differential genotypic effects on
hyperlocomotion. To delineate this issue, we used the
skeletal ryanodine receptor blocker dantrolene as a muscle
Figure 7 The basal ganglia and cerebellum are involved in motor control. Both circuitries receive projections from the cerebral cortex and
send signals to the thalamus. These signals are then accumulated in the cerebral cortex. The inhibitory regulation from the basal ganglia and
stimulatory regulation from the cerebellum modulate the activity of the cerebral cortex. UBP141 inhibited the NR2C subunit in both WT and
GluN2D KO mice but only inhibited the NR2D subunit in WT mice. Thus, the inhibition of the GluN2D subunit is a more important factor for
motor impairment than the inhibition of the GluN2C subunit. Similarly, CIQ potentiated the function of the GluN2C/2D subunit of the NMDA
receptor in WT mice but potentiated only the GluN2C subunit in GluN2D KO mice. The potentiation of both the GluN2C and GluN2D subunits
did not induce motor impairment in WT mice but induced motor impairment in GluN2D KO mice. Based on the balance between two
competing forces, goal-directed movements could be appropriately performed. Figure is modified from [16]. Red arrows indicate excitatory pathways;
gray arrows indicate inhibitory pathways. BS/SC, brain stem/spinal cord; CBC, cerebellar cortex; CM, centromedian nucleus of the thalamus; DCN, deep
cerebellar nuclei; GPe, globus pallidus external segment; GPi, globus pallidus internal segment; Pf, parafascicular nucleus of the thalamus; PN, pontine
nucleus; PPN, pedunculopontine nucleus; SNr, substantia nigra pars reticulate; SNc, substantia nigra pars compacta; Sth, subthalamic nucleus;
VA, ventral anterior nucleus of the thalamus; Vim, ventral intermediate nucleus of the thalamus; VL, ventrolateral nucleus of the thalamus.
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tion. Dantrolene itself did not inhibit basal c-fos ex-
pression or PCP-induced c-fos expression in WT mice
(Figure 6C, D) without PCP-induced hyperlocomotion.
Thus, these results indicate that the genotypic diffe-
rence in PCP-induced c-fos expression was not secon-
dary to hyperlocomotion in WT mice.
These brain areas, including the striatum, thalamus,
motor cortex, and subthalamic nucleus, are components
of the basal ganglia circuitry that mediates various motor
functions, such as movement control, behavioral per-
formance, and motivational processes [17-21]. A standard
model of the basal ganglia circuitry suggests that direct
projections from the subthalamic nucleus to output struc-
tures play a major role in motor function regulation
[22-24]. Interestingly, NMDA receptors in the subtha-
lamic nucleus and globus pallidus are mainly composed of
GluN1 and GluN2D subunits [25]. Therefore, genetic ab-
lation of the GluN2D subunit likely results in the severe
loss of NMDA receptor function in the subthalamic nu-
cleus and globus pallidus in GluN2D KO mice. Acute
PCP administration (2 mg/kg) increased extracellularglutamate levels in the prefrontal cortex [26]. Considering
that motor and prefrontal cortical areas provide a major
source of glutamatergic excitatory inputs to the subthalamic
nucleus [27-29], activated glutamatergic inputs to NMDA
receptors via the subthalamic nucleus would be attenuated
in GluN2D KO mice. Therefore, the mechanisms respon-
sible for resistance against PCP-induced motor impair-
ment in GluN2D KO mice may involve dysfunction of
NMDA receptors in basal ganglia circuitry caused by a
lack of GluN2D subunits.
PCP-induced changes in the expression of genes related
to cellular stress are attenuated by genetic ablation of
the GluN2D subunit
Egr4, which displays a neural-specific pattern of ex-
pression, is rapidly upregulated by neuronal activity
[30-32]. Interestingly, the expression of Egr4 (NGFI-C)
was potently decreased by PCP administration in the
thalamus and striatum in GluN2D KO mice (Tables 1
and 2). In contrast, Egr4 expression in the frontal cor-
tex in WT mice was increased by PCP administration.
These results suggest that PCP administration induced
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KO mice.
PCP caused selective increases in the expression of
several genes in WT mice, including Ddit4 (REDD1),
Bag-3, Txnip, and Sesn1. These genes are related to cel-
lular stress. For example, REDD1 (also known as RTP801/
Dig2/DDIT4) is a critical transducer of cellular responses
to energy depletion through the TSC-mTOR pathway.
Mammalian REDD1 is induced following DNA damage
through both p53-dependent and -independent mecha-
nisms [33]. Recently, Jin et al. (2011) found that TXNIP
inhibited mTOR activity by binding to and stabilizing the
Redd1 protein [34]. In response to stress, p53 transcribes
a group of critical negative regulators of these two path-
ways, including Sestrin1. BAG-3, a key component of the
proteostasis machinery, is induced under oxidative stress
and upon proteasome inhibition [35-37]. BAG-3 triggers
the recruitment of the autophagic ubiquitin adaptor p62
and thus facilitates substrate degradation through the
autophagosome lysosome pathway [35]. Therefore, the
PCP-induced increases in the gene expression of Sestrin 1,
Bag-3, and Ddit4 (REDD1) in WT mice are related to cellu-
lar stress, DNA damage, and the autophagosome lysosome
pathway. The lack of increased expression of these genes in
GluN2D KO mice after PCP administration suggests that
ablation of the GluN2D subunit may prevent PCP-induced
cellular stress in the striatum and frontal cortex.
Concluding remarks
In the present study, we found that PCP-induced motor
impairment was reduced in GluN2D KO mice. Although
the GluN2D subunit population is rather low and re-
stricted in the mature brain, we conclude that the GluN2D
subunit plays an important role in PCP-induced motor
impairment and gene expression.
Materials and methods
Materials
Phencyclidine (Shionogi Pharmaceutical Co. Ltd., Osaka,
Japan) was dissolved in saline. UBP141 (Abcam Biochemi-
cals; http://www.ascentscientific.com/; accessed June 7,
2013) was dissolved in twice an equal molar amount of
NaOH solution, diluted with saline, and neutralized to
pH 8.0. Prof. Stephen F. Traynelis kindly provided CIQ to
us. CIQ was dissolved in dimethylacetamide, and four vo-
lumes of PEG-400 were then added and gently mixed. Fi-
nally, five volumes of 5% glucose solution were added.
After preparation, the CIQ solution was immediately used.
Dantrolene (Sigma-Aldrich, St. Louis, MO, USA) was
freshly dissolved in warm water (50°C) by sonication.
Animals
The experimental protocols were approved by the Ani-
mal Use and Care Committee of the Tokyo MetropolitanInstitute of Medical Science. The mice were housed 5–6
per cage with free access to food and water and main-
tained on a 12 h/12 h light/dark cycle.
Three-month-old homozygous GluN2D mutant and
WT mice of both sexes were obtained by crossing F11
heterozygous GluN2D mutant mice (+/−) on a 99.99%
pure C57BL/6 genetic background [2]. WT and homozy-
gous KO mice were genotyped by polymerase chain re-
action (PCR) using two internal primers (one targeted at
the neomycin-resistant gene [NEO] insertion in the KO
construct and one targeted at the WT gene) and one ex-
ternal primer, generating two products that identified
the WT and KO genes. Polymerase chain reaction using
Go Taq DNA polymerase (Promega, Madison, WI, USA)
was performed on ear DNA eluted after overnight diges-
tion by proteinase K. The forward primer (5′-GAG ATT
GAG ATG CTG GAG CGG CTG-3′) and WT primer
(5′-CGG CGG TGG CGG GGG TTT GGC-3′) pro-
duced a 455-base pair (bp) band, whereas the forward
primer and NEO primer (5′-GTG GAT GTG GAA TGT
GTG CGA GGC-3′) produced a 184-bp band. The PCR
amplification products were electrophoretically sepa-
rated on 2% agarose gels, and the bands were visualized
under ultraviolet illumination.
Rotarod test
A commercially available rotarod apparatus was used
(KN-75, Natsume Seisakusho Co., Ltd, Tokyo, Japan).
During the training phase, the mice underwent a train-
ing session on the apparatus for five training trials, in
which the rod (3 cm diameter) was maintained at a
constant speed for 300 s. The rod was kept stationary
for the first trial and held at 6 rotations per minute
(rpm) for two trials. The rod was then rotated at
12 rpm for two training trials, with a 3-h intertrial
interval (ITI). The mice that were able to stay on the
rod at 12 rpm for more than 200 s were evaluated in
the test phase the next day (day 2 in Figure 1A). After
the training phase, 93.3% and 90.9% of the WT and
GluN2D KO mice, respectively, had proceeded to the
test phase.
During the test phase, two trials were conducted with
a 3-h ITI. In the first trial, the mice were placed on the
rod that rotated at 12 rpm, at which time a timer was
started and maintained for 300 s (day 3 in Figure 1A).
The second trial was performed 30 min after PCP
(3 mg/kg, subcutaneously [s.c.]) and CIQ (20 mg/kg, in-
traperitoneally [i.p.]) administration at 12 rpm or UBP141
administration (24.3 μg, 20 μl of 3 mM per mouse, intra-
cisternally [i.c.], under diethyl ether anesthesia) at 0 rpm.
The second trial lasted 300 s. The latency to fall from the
rod was recorded for each of the two successive trials. For
the animal studies, Fisher’s exact test was used to compare
the data.
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microarray hybridization
Preliminary experiment: Gene expression analyses using
cDNA array
WT and GluN2D KO mice were injected with saline or
PCP (10 mg/kg, s.c.). Two hours after the injection, the
striata from 10 mice per treatment group (a total of 160
mice were used) were quickly dissected on ice and im-
mediately frozen at −80°C. The precise procedure for
the cDNA array experiments is described elsewhere [38].
This developed a cDNA array system that utilized mouse
KIAA-homologous cDNA (mKIAA) clones (http://www.
kazusa.or.jp/rouge/; accessed July 7, 2013). KIAA clones
were originally obtained from a human cDNA sequencing
project to accumulate protein-coding sequence informa-
tion on unidentified human genes. Although unidentified
mKIAA genes are interesting, the expression data of newly
identified mKIAA genes is not suitable for pathway
analysis.
Experiment 1. Gene expression analyses using Illumina
DNA array
WT and GluN2D KO mice were injected with saline or
PCP (10 mg/kg, s.c.). Four groups, consisting of saline-
treated WT, saline-treated GluN2D KO, PCP-treated
WT, and PCP-treated GluN2D KO mice, were prepared.
One group included four samples. One sample is pre-
pared with more than three mice. We used 16 samples
and the16 cDNA arrays. Total RNA was isolated with
TRIzol reagent (Invitrogen, Carlsbad, CA, USA) and purified
using the RNeasy Mini Kit according to the manufacturer’s
instructions (Qiagen, Valencia, CA, USA). RNA was quanti-
fied by measuring the optical density at 260 nm using a
spectrophotometer (Beckman, Fullerton, CA, USA).
Gene expression profiling for 16 different RNA sam-
ples was performed using microarray platforms from
Illumina (San Diego, CA, USA). For the Illumina plat-
form, we used the multi-sample MouseRef-8 BeadChip
format with greater than 24,000 probes that simultan-
eously profile eight samples on a single chip. Briefly, 500
ng of total RNA was labeled using an Illumina TotalPrep
RNA Amplification Kit (Life Technologies, Carlsbad, CA,
USA). Double-stranded cDNA was synthesized using
T7-oligo (dT) primers followed by an in vitro tran-
scription reaction to amplify antisense-RNA (aRNA).
Biotin was incorporated into the synthesized aRNA
target. The biotinylated cRNA target was hybridized to
the MouseRef-8 BeadChip. Hybridization, washing, and
scanning were performed according to the manufacturer’s
instructions following overnight hybridization. The chips
were scanned using a BeadScan (Illumina) at a multiplier
setting of “2.” The microarray images were recorded, and
gene expression data were automatically extracted accord-
ing to the manufacturer’s default settings. Raw microarrayintensity data were provided using differential expression
algorithms (Illumina). Additional calculations were per-
formed within a Microsoft Excel spreadsheet. For each
probe, intensity data were used in t-tests to obtain p-values
and fold changes. Genes with a fold change > 1.3 or < 0.7
and between-group differences with p < 0.05 were consid-
ered to be differentially expressed genes (DEGs; [39]. The
pathway analyses of statistically significant genes were per-
formed using MetaCore software (GeneGo, St. Joseph, MI,
USA). The figures in the text are adaptations based on the
figures created by MetaCore software.
Real-time qRT-PCR
To confirm the cDNA array results, quantitative reverse-
transcription PCR (qRT-PCR) was performed. Purified
mRNA (0.5 μg) was reverse-transcribed with random
nonamers using the SuperScript III first-strand synthe-
sis system according to the manufacturer’s instructions
(Invitrogen). To evaluate gene expression, real-time qRT-
PCR was performed using the SYBR-green-based real-
time qRT-PCR assay. Using the primers identified by
Lasergene (DNASTAR, Madison, WI, USA), qRT-PCR
was performed. First-strand cDNA from the pooled
mRNA was used as a template in a 25-μl PCR reaction
with 200 nM primers and the Power SYBR Green PCR
Master Mix (Applied Biosystems, Warrington, UK). Forty-
five cycles of PCR were performed with an Applied Biosys-
tems 7300 Real Time PCR System (Applied Biosystems).
The levels of all of the cDNAs generated from the mRNA
by reverse transcription were calculated using the standard
curve method for quantification and normalized to actin
transcript levels.
To confirm the Illumina DNA array results, qRT-PCR
experiments were performed using LightCycler 480 and
LightCycler 480 Probes Master (Roche, Indianapolis, IN,
USA) according to the manufacturer’s protocol. Se-
quences for gene-specific primers that corresponded to
the PCR targets were obtained using LightCycler Probe
Design software (Roche). The primers were synthesized
and purified by high-performance liquid chromatog-
raphy by Nihon Gene Research Laboratories (Sendai,
Japan). Quantitative PCR values were normalized to actin
levels.
To examine c-fos mRNA levels by qRT-PCR, the mice
were injected with UBP141, CIQ, and control vehicles
similarly to the procedure used in the rotarod test but
without behavioral testing. Two hours after injection,
the thalamus and striatum from each mouse were
quickly dissected on ice and immediately frozen at −80°C.
Similarly, the mice first received dantrolene (5 mg/kg, i.p.)
and then injected with PCP (10 mg/kg, s.c.) 15 min later.
Two hours after the PCP injection, the thalamus and stri-
atum from each mouse were quickly dissected on ice and
immediately frozen at −80°C. Total RNA was separately
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were performed using LightCycler 480 and LightCycler
480 Probes Master (Roche, Indianapolis, IN, USA) accord-
ing to the manufacturer’s protocol.
Immunohistochemistry
All of the animals were deeply anesthetized with an over-
dose of sodium pentobarbital (50 mg/kg, i.p.; Nembutal,
Dainippon-Sumitomo, Osaka, Japan) and transcardially per-
fused with 50 ml phosphate-buffered saline (PBS), followed
by ice-cold 4% paraformaldehyde in 0.1 M phosphate buffer
(PB; pH 7.4). The brains were quickly removed from the
skull and post-fixed overnight in the same fixative. After
post-fixation, the brains were cryoprotected in 20% sucrose
in PB (0.1 M, pH 7.4) for 2 days at 4°C and serially sec-
tioned (50-μM thickness) using a Leica VT1000 P vibra-
tome (Leica Microsystems). For the immunohistochemical
visualization of Fos expression, coronal brain sections were
pretreated for 15 min at room temperature with a 1%
hydrogen peroxide solution to remove peroxidases. The
sections were blocked for 2 h at room temperature in 4%
goat serum solution (0.05% Tween-20/Tris-buffered sa-
line), followed by incubation for 48 h at 4ºC in the primary
Fos antibody (anti-Fos; 1:10,000; Ab-5, Calbiochem) in PBS
with 4% normal goat serum. Immunoreactivity was visua-
lized using ImmPRESS reagent (Vector Labs, Burlingame,
CA, USA) with 3,3′-diaminobenzidine/nickel as the
chromogen. Control and experimental tissues from
each group were processed in parallel. No staining was
observed in the brain sections with omission of either
the primary or secondary antibody.
Cell counting
The number of Fos-positive neurons within the confines
of each anatomically demarcated nucleus was evaluated
using bright-field microscopy at 20× magnification. Based
on Fos expression and its relevance to motor function, the
following brain regions were selected for counting Fos-
immunoreactive cells: striatum (0.98 mm), thalamus
(−2.06 mm), paraventricular thalamic nucleus (−1.46),
cingulate cortex and motor cortex (1.7 mm), and sub-
thalamic nucleus (−2.18 mm). Bregma-based coordi-
nates [10] are shown in parentheses after each brain
region. The analyses of Fos-immunoreactive nuclei were
performed using a Keyence microscope system (Keyence
BZ-8100, Woodcliff Lake, NJ, USA). Twenty to 30 photo-
graphs (one photograph was extracted from five super-
imposed photographs at different depths) per coronal slice
were taken in the selected regions. Full-image reconstruc-
tion of the entire slice was performed using Keyence BZ-
8100. The areas that contained the striatum and other
brain areas were cut off using Adobe Photoshop Elements
software and transferred to NIH ImageJ software to auto-
matically count Fos-labeled cells in the region of interestas defined by the template. The number of Fos-positive
cells was normalized to the area (mm2).
Statistical analyses
Parametric or nonparametric analysis of variance (ANOVA)
and appropriate post hoc tests were used to assess the effects
of treatments, depending on the initial analyses of distribu-
tion normality. Correlation analyses were performed using
Pearson’s coefficient. In the rotarod test, the data after 300 s
were not recorded because the measurement of motor per-
formance concluded at 300 s. To analyze the results from
the rotarod test, Fisher’s exact test was used. Statistical sig-
nificance was set at p < 0.05.
Additional files
Additional file 1: Table S1 Calculated gene expression data from raw
microarray intensity data (multi-sample MouseRef-8 BeadChip).WPCP,
PCP-injected WT mice; WS, saline-injected WT mice; KOS, saline-injected
GluN2D KO mice; KOPCP, PCP-injected GluN2D KO mice.
Additional file 2: Table S2 Numerical data of Figure 6 (c-fos/actin)
and these reference data (actin). Two hours after the injection of
(A) UBP141 (3 mM, 20 μl, i.c.), (B) CIQ (20 mg/kg, i.p.), (C, D) Dantrolene
(5 mg/kg, i.p.) and PCP (10 mg/kg, s.c), c-fos and actin expressions were
measured using qRT-PCR analyses. The ratio of c-fos/actin transcripts and
its reference actin transcripts are shown as the mean ± SEM fold change
from saline controls in WT mice.
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